Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient

Tatsuo MoritaDepartment of Urology, Jichi Medical University, Tochigi, JapanAbstract: A 67-year-old man was refered to our institution with a complaint of elevated serum prostate-specific antigen (PSA) level (54 ng/mL). Diagnosis was adenocarcinoma of the prostate with a Gleason score of 9, with bon...

Full description

Bibliographic Details
Main Author: Tatsuo Morita
Format: Article
Language:English
Published: Dove Medical Press 2010-04-01
Series:International Medical Case Reports Journal
Online Access:http://www.dovepress.com/marked-leukocytosis-in-response-to-estramustine-phosphate-in-a-hormone-a4273
Description
Summary:Tatsuo MoritaDepartment of Urology, Jichi Medical University, Tochigi, JapanAbstract: A 67-year-old man was refered to our institution with a complaint of elevated serum prostate-specific antigen (PSA) level (54 ng/mL). Diagnosis was adenocarcinoma of the prostate with a Gleason score of 9, with bone metastasis (stageD2). He was treated with maximal androgen blockade followed by estramustine phosphate (EMP) because of the progression to hormone-refractory prostate cancer (HRPC). Leukocytosis over 20000/μL was repeatedly observed at each administration of EMP. This is the first case report of leukocytosis in response to EMP in an HRPC patient. The present case suggests that EMP could modulate leukocyte differentiation in HRPC patients.Keywords: leukocytosis, neutrophilia, estramustine phosphate, hormone-refractory prostate cancer
ISSN:1179-142X